SE9304060D0 - Sätt att selektera specifika bakteriofager - Google Patents

Sätt att selektera specifika bakteriofager

Info

Publication number
SE9304060D0
SE9304060D0 SE9304060A SE9304060A SE9304060D0 SE 9304060 D0 SE9304060 D0 SE 9304060D0 SE 9304060 A SE9304060 A SE 9304060A SE 9304060 A SE9304060 A SE 9304060A SE 9304060 D0 SE9304060 D0 SE 9304060D0
Authority
SE
Sweden
Prior art keywords
phage
pct
molecule
protein
methods
Prior art date
Application number
SE9304060A
Other languages
English (en)
Swedish (sv)
Inventor
Carl A K Borrebaeck
Original Assignee
Bioinvent Int Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioinvent Int Ab filed Critical Bioinvent Int Ab
Priority to SE9304060A priority Critical patent/SE9304060D0/xx
Publication of SE9304060D0 publication Critical patent/SE9304060D0/xx
Priority to US08/640,792 priority patent/US5712089A/en
Priority to AU12521/95A priority patent/AU686292B2/en
Priority to JP51614195A priority patent/JP3574135B2/ja
Priority to CA002178205A priority patent/CA2178205A1/en
Priority to EP95903485A priority patent/EP0739413B1/en
Priority to ES95903485T priority patent/ES2132601T3/es
Priority to DK95903485T priority patent/DK0739413T3/da
Priority to DE69417446T priority patent/DE69417446T2/de
Priority to AT95903485T priority patent/ATE178092T1/de
Priority to PCT/SE1994/001166 priority patent/WO1995016027A1/en
Priority to GR990401295T priority patent/GR3030210T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SE9304060A 1993-12-06 1993-12-06 Sätt att selektera specifika bakteriofager SE9304060D0 (sv)

Priority Applications (12)

Application Number Priority Date Filing Date Title
SE9304060A SE9304060D0 (sv) 1993-12-06 1993-12-06 Sätt att selektera specifika bakteriofager
PCT/SE1994/001166 WO1995016027A1 (en) 1993-12-06 1994-12-05 Method of selecting specific bacteriophages
CA002178205A CA2178205A1 (en) 1993-12-06 1994-12-05 Method of selecting specific bacteriophages
AU12521/95A AU686292B2 (en) 1993-12-06 1994-12-05 Method of selecting specific bacteriophages
JP51614195A JP3574135B2 (ja) 1993-12-06 1994-12-05 特異的バクテリオファージの選択方法
US08/640,792 US5712089A (en) 1993-12-06 1994-12-05 Method of selecting specific bacteriophages
EP95903485A EP0739413B1 (en) 1993-12-06 1994-12-05 Method of selecting specific bacteriophages
ES95903485T ES2132601T3 (es) 1993-12-06 1994-12-05 Procedimiento para la seleccion de bacteriofagos especificos.
DK95903485T DK0739413T3 (da) 1993-12-06 1994-12-05 Fremgangsmåde til udvælgelse af specifikke bakteriofager
DE69417446T DE69417446T2 (de) 1993-12-06 1994-12-05 Methode zur selektion spezifischer bakteriophagen
AT95903485T ATE178092T1 (de) 1993-12-06 1994-12-05 Methode zur selektion spezifischer bakteriophagen
GR990401295T GR3030210T3 (en) 1993-12-06 1999-05-13 Method of selecting specific bacteriophages

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9304060A SE9304060D0 (sv) 1993-12-06 1993-12-06 Sätt att selektera specifika bakteriofager

Publications (1)

Publication Number Publication Date
SE9304060D0 true SE9304060D0 (sv) 1993-12-06

Family

ID=20392016

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9304060A SE9304060D0 (sv) 1993-12-06 1993-12-06 Sätt att selektera specifika bakteriofager

Country Status (12)

Country Link
US (1) US5712089A (xx)
EP (1) EP0739413B1 (xx)
JP (1) JP3574135B2 (xx)
AT (1) ATE178092T1 (xx)
AU (1) AU686292B2 (xx)
CA (1) CA2178205A1 (xx)
DE (1) DE69417446T2 (xx)
DK (1) DK0739413T3 (xx)
ES (1) ES2132601T3 (xx)
GR (1) GR3030210T3 (xx)
SE (1) SE9304060D0 (xx)
WO (1) WO1995016027A1 (xx)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69129154T2 (de) * 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
GB9500851D0 (en) * 1995-01-17 1995-03-08 Bionvent International Ab Method of selecting specific bacteriophages
SE9503151D0 (sv) * 1995-09-13 1995-09-13 Bioinvent Internatioal Ab Combined ligand and receptor display
SE506771C2 (sv) * 1996-02-06 1998-02-09 Gotpat 105 Ab Fusionsprotein, bakteriofag uttryckande proteinet, dessas användning samt hybridoma celler och monoklonaler producerade av cellerna
US6174915B1 (en) 1997-03-25 2001-01-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
US6497874B1 (en) 1997-02-05 2002-12-24 Maardh Sven Recombinant phages
GB9716900D0 (en) * 1997-08-08 1997-10-15 Bioinvent Int Ab Method for selecting phage displaying ligand binders
EP1518927A3 (en) * 1998-02-11 2005-06-22 Maxygen, Inc. Optimization of immunomodulatory properties of genetic vaccines
JP2002507392A (ja) * 1998-02-11 2002-03-12 マキシジェン， インコーポレイテッド 遺伝子ワクチンの免疫調節特性の最適化
US7153655B2 (en) * 1998-06-16 2006-12-26 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence
IL140918A0 (en) 1998-07-27 2002-02-10 Genentech Inc Improved transformation efficiency in phage display through modification of a coat protein
AU784983B2 (en) * 1999-12-15 2006-08-17 Genentech Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
CN100390288C (zh) 2000-04-11 2008-05-28 杰南技术公司 多价抗体及其应用
US6686154B2 (en) * 2000-06-05 2004-02-03 Zyomyx, Inc. Screening of phage displayed peptides without clearing of the cell culture
EP2014303A2 (en) 2000-07-27 2009-01-14 Genentech, Inc. APO-2L receptor agonist and CPT-11 synergism
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US6958213B2 (en) 2000-12-12 2005-10-25 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function
US20020086292A1 (en) 2000-12-22 2002-07-04 Shigeaki Harayama Synthesis of hybrid polynucleotide molecules using single-stranded polynucleotide molecules
US7262012B2 (en) * 2002-05-17 2007-08-28 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function using varied exonuclease digestion in two polynucleotide populations
KR20050083774A (ko) 2002-10-16 2005-08-26 유로-셀티크 소시에떼 아노뉨 세포-연관된 ｃａ 125/ｏ772ｐ에 결합하는 항체들 및그것의 용도의 방법들
GB2400851B (en) * 2003-04-25 2004-12-15 Bioinvent Int Ab Identifying binding of a polypeptide to a polypeptide target
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
AU2005250369A1 (en) * 2004-05-18 2005-12-15 Genentech, Inc. M13 virus major coat protein variants for C-terminal and BI-terminal display of a heterologous protein
GB2432366B (en) * 2005-11-19 2007-11-21 Alligator Bioscience Ab A method for in vitro molecular evolution of protein function
MX2010010137A (es) 2008-03-14 2010-10-25 Allergan Inc Ensayos inmuno-basados de la actividad del serotipo a de la toxina botulinica.
RU2010151562A (ru) 2008-06-20 2012-07-27 ВАЙЕТ ЭлЭлСи (US) Композиции и способы применения orf1358 из бета-гемолитических стрептококковых штаммов
MX2011001409A (es) 2008-08-14 2011-03-29 Cephalon Australia Pty Ltd Anticuerpos anti-il-12/il-23.
CA3073384A1 (en) * 2008-09-05 2010-03-11 President And Fellows Of Harvard College Continuous directed evolution of proteins and nucleic acids
DK2406629T5 (en) 2009-03-13 2014-03-03 Allergan Inc IMMUNE BASED retargeted ENDOPEPTIDASEAKTIVITETSASSAYS
CA2807244A1 (en) * 2010-08-27 2012-03-01 University Of Zurich A novel diagnostic and therapeutic target in inflammatory and/or cardiovascular diseases
WO2012088381A2 (en) 2010-12-22 2012-06-28 President And Fellows Of Harvard College Continuous directed evolution
GB201200259D0 (en) 2012-01-09 2012-02-22 Ohlin Per M Novel therapies
CA2907234A1 (en) 2013-03-15 2014-09-25 Altria Client Services Llc Bacteriophage and methods of making and using
AU2014359085B2 (en) 2013-12-08 2017-11-02 Peptcell Limited HIV antigens and antibodies and compositions, methods and uses thereof
SG10201805933TA (en) 2013-12-24 2018-08-30 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
WO2015134121A2 (en) 2014-01-20 2015-09-11 President And Fellows Of Harvard College Negative selection and stringency modulation in continuous evolution systems
US10920208B2 (en) 2014-10-22 2021-02-16 President And Fellows Of Harvard College Evolution of proteases
WO2016123427A1 (en) 2015-01-29 2016-08-04 Altria Client Services Llc Bacteriophage and methods of using
US10357056B2 (en) 2015-01-29 2019-07-23 Altria Client Services Llc Endolysin from bacteriophage against Geobacillus and methods of using
US11299729B2 (en) 2015-04-17 2022-04-12 President And Fellows Of Harvard College Vector-based mutagenesis system
CA2990360C (en) 2015-06-24 2024-02-13 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
WO2017015545A1 (en) 2015-07-22 2017-01-26 President And Fellows Of Harvard College Evolution of site-specific recombinases
US11524983B2 (en) 2015-07-23 2022-12-13 President And Fellows Of Harvard College Evolution of Bt toxins
US10612011B2 (en) 2015-07-30 2020-04-07 President And Fellows Of Harvard College Evolution of TALENs
US12043852B2 (en) 2015-10-23 2024-07-23 President And Fellows Of Harvard College Evolved Cas9 proteins for gene editing
WO2017137830A1 (en) 2016-02-12 2017-08-17 Janssen Pharmaceutica Nv Anti-vista (b7h5) antibodies
CA3019164A1 (en) 2016-03-29 2017-10-05 Janssen Biotech, Inc. Method of treating psoriasis with increased interval dosing of anti-il12/23 antibody
WO2017175058A1 (en) 2016-04-07 2017-10-12 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
AU2017336799B2 (en) 2016-09-30 2023-08-31 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-IL23 specific antibody
EP3312290A1 (en) 2016-10-18 2018-04-25 Ipsen Biopharm Limited Cellular vamp cleavage assay
EP3541422A4 (en) 2016-11-16 2020-05-06 Janssen Biotech, Inc. METHOD FOR TREATING PSORIASIS WITH A SPECIFIC ANTI-IL-23 ANTIBODY
EP3573658A4 (en) 2017-01-30 2021-07-21 Janssen Biotech, Inc. ANTI-TNF ANTIBODIES, COMPOSITIONS, AND METHODS FOR TREATMENT OF ACTIVE PSORIATIC ARTHRITIS
CA3052578A1 (en) 2017-02-07 2018-08-16 Janssen Biotech, Inc. Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
WO2019010164A1 (en) 2017-07-06 2019-01-10 President And Fellows Of Harvard College EVOLUTION OF ARNT SYNTHÉTASES
US11624130B2 (en) 2017-09-18 2023-04-11 President And Fellows Of Harvard College Continuous evolution for stabilized proteins
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
WO2019150309A1 (en) 2018-02-02 2019-08-08 Hammack Scott Modulators of gpr68 and uses thereof for treating and preventing diseases
MX2020009265A (es) 2018-03-05 2020-10-01 Janssen Biotech Inc Metodos para tratar la enfermedad de crohn con un anticuerpo especifico anti-il23.
WO2019241649A1 (en) 2018-06-14 2019-12-19 President And Fellows Of Harvard College Evolution of cytidine deaminases
WO2020016838A2 (en) 2018-07-18 2020-01-23 Janssen Biotech, Inc. Sustained response predictors after treatment with anti-il23 specific antibody
JP7359845B2 (ja) 2018-09-24 2023-10-11 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ１２／ｉｌ２３抗体で潰瘍性大腸炎を治療する安全かつ有効な方法
EP3883607A4 (en) 2018-11-20 2022-08-17 Janssen Biotech, Inc. SAFE AND EFFECTIVE PROCESS FOR TREATING PSORIASIS WITH A SPECIFIC ANTI-IL-23 ANTIBODY
MA54562A (fr) 2018-12-18 2021-10-27 Janssen Biotech Inc Méthode sûre et efficace de traitement du lupus avec un anticorps anti-il12/il23
WO2020148651A1 (en) 2019-01-15 2020-07-23 Janssen Biotech, Inc. Anti-tnf antibody compositions and methods for the treatment of juvenile idiopathic arthritis
JP2022518250A (ja) 2019-01-23 2022-03-14 ヤンセン バイオテツク，インコーポレーテツド 乾癬性関節炎の治療方法で使用するための抗ｔｎｆ抗体組成物
EP3938391A1 (en) 2019-03-14 2022-01-19 Janssen Biotech, Inc. Methods for producing anti-tnf antibody compositions
JP2022525179A (ja) 2019-03-14 2022-05-11 ヤンセン バイオテツク，インコーポレーテツド 抗ｔｎｆ抗体組成物を産生するための産生方法
US20200291107A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Manufacturing Methods for Producing Anti-IL12/IL23 Antibody Compositions
WO2020183271A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Methods for producing anti-tnf antibody compositions
WO2020188466A1 (en) 2019-03-18 2020-09-24 Janssen Biotech, Inc. Method of treating psoriasis in pediatric subjects with anti-il12/il23 antibody
EP3972690A4 (en) 2019-05-23 2023-07-05 Janssen Biotech, Inc. METHOD OF TREATMENT OF INFLAMMATORY BOWEL DISEASE USING COMBINATION THERAPY OF ANTIBODIES TO IL-23 AND TNF-ALPHA
CN114173873A (zh) 2019-06-03 2022-03-11 詹森生物科技公司 用于治疗活动性强直性脊柱炎的抗tnf抗体、组合物和方法
US20220323580A1 (en) 2019-06-03 2022-10-13 Janssen Biotech, Inc. Anti-tnf antibody compositions, and methods for the treatment of psoriatic arthritis
WO2021028752A1 (en) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anti-tfn antibodies for treating type i diabetes
MX2023010697A (es) 2021-03-12 2023-11-23 Janssen Biotech Inc Método para tratar pacientes con artritis psoriásica con respuesta inadecuada a la terapia de tnf con anticuerpo específico anti-il23.
AU2022233792A1 (en) 2021-03-12 2023-10-26 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
KR20240032991A (ko) 2021-07-09 2024-03-12 얀센 바이오테크 인코포레이티드 항-tnf 항체 조성물의 생성을 위한 제조 방법
AU2022306144A1 (en) 2021-07-09 2024-02-22 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
US20230038355A1 (en) 2021-07-09 2023-02-09 Janssen Biotech, Inc. Manufacturing Methods for Producing Anti-IL12/IL23 Antibody Compositions
IL312401A (en) 2021-10-29 2024-06-01 Janssen Biotech Inc Methods for treating Crohn's disease with a specific anti-IL23 antibody
KR20240107176A (ko) 2021-11-15 2024-07-08 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체로 크론병을 치료하는 방법
KR20240103043A (ko) 2021-11-23 2024-07-03 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체로 궤양성 결장염을 치료하는 방법
US20230312703A1 (en) 2022-03-30 2023-10-05 Janssen Biotech, Inc. Method of Treating Psoriasis with IL-23 Specific Antibody
WO2023223265A1 (en) 2022-05-18 2023-11-23 Janssen Biotech, Inc. Method for evaluating and treating psoriatic arthritis with il23 antibody
US20240199734A1 (en) 2022-11-22 2024-06-20 Janssen Biotech, Inc. Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4122599C2 (de) * 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
EP0614989A1 (en) * 1993-02-17 1994-09-14 MorphoSys AG A method for in vivo selection of ligand-binding proteins

Also Published As

Publication number Publication date
EP0739413A1 (en) 1996-10-30
US5712089A (en) 1998-01-27
DE69417446T2 (de) 1999-09-02
WO1995016027A1 (en) 1995-06-15
JP3574135B2 (ja) 2004-10-06
DE69417446D1 (de) 1999-04-29
JPH09506000A (ja) 1997-06-17
AU686292B2 (en) 1998-02-05
ES2132601T3 (es) 1999-08-16
CA2178205A1 (en) 1995-06-15
ATE178092T1 (de) 1999-04-15
DK0739413T3 (da) 1999-10-11
AU1252195A (en) 1995-06-27
GR3030210T3 (en) 1999-08-31
EP0739413B1 (en) 1999-03-24

Similar Documents

Publication Publication Date Title
SE9304060D0 (sv) Sätt att selektera specifika bakteriofager
ATE169058T1 (de) Gegen cd3 gerichtete antikörper
NO964650D0 (no) LAG-3 protein-opplöselige polypeptidfraksjoner, fremgangsmåte for fremstilling, teraupeutisk preparat og anti-idiotype antistoff
WO1999062526A3 (en) Use of genetically engineered antibodies to cd38 to treat multiple myeloma
ES2106195T3 (es) Anticuerpo igg aglicosilado anti cd3.
DK0523395T3 (da) Seroreaktive områder på proteinerne E1 og E2 i HPV 16
ATE301471T1 (de) Verwendung von antikörpen gegen cd45ro leukozytenantigen zur immunmodulation
DE69833106D1 (de) Antigene fusionsproteine, die gal-alpha-1,3-gal-epitope enthalten.
UA29494C2 (uk) Гуманізовані антитіла, способи їх продукування, спосіб лікування хвороби крона, спосіб лікування розсіяного склерозу, фармацевтична композиція
GR3036906T3 (en) Monoclonal antibody which specifically binds to tumor vascular endothelium and uses thereof.
FI854187L (fi) Immunoanalyser foer denaturerade proteinanalyser, saerskilt hb alc, samt antikroppar anvaendbara i dessa.
DK0626861T4 (da) Behandling af astma.
WO1999003987A3 (fr) Epitopes du vrs et anticorps les comportant, utiles dans le diagnostic et la therapie
DE59508474D1 (de) RHEUMAFAKTOR-ENTSTÖRUNG MIT ANTI-Fd-ANTIKÖRPERN
DE69622259D1 (de) Cd40 bindendes protein zur stimulierung der immunantwort
ATE206621T1 (de) Il-8 antagonisten zur behandlung von asthma
DK0547200T3 (da) Rekombinante antistoffer på overfladen af E. coli
CA2126182A1 (en) Humanized antibodies reactive with gpiib/iiia
DE69216600D1 (de) Synthetisches CDw52(CAMPATH-1) Peptidantigen
ATE111606T1 (de) Ein gattungsspezifisches listeria-antigen, identifiziert durch monoklonale antikörper.
HUT69623A (en) Use of endotheli- leukocyte adhesion molecule-1 and antibodies thereto in the treatment of asthma
ES546594A0 (es) Un procedimiento para preparar un anticuerpo monocional anti-urocinasa.
ATE328088T1 (de) Transketolase-verwandtes protein
KR890009417A (ko) 모노크로날 항체의 제조방법 및 그것의 이용방법
AU1626492A (en) Monoclonal antibodies against the plasmin-antiplasmin complex, a method for the preparation thereof and the use thereof